Eugean Jiwanmall, MPH, MBA

March 11, 2022

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

March 11, 2022

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

March 11, 2022

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

March 04, 2022

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.

February 25, 2022

Criteria used by payers to determine how to code and support the use of various genomic profiling assays used in oncology.

February 18, 2022

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

February 11, 2022

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

February 03, 2022

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

January 28, 2022

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.

January 21, 2022

Payer perspective regarding updates to coverage for comprehensive genomic profiling, becoming more widely used in oncology practice.